<SEC-DOCUMENT>0001628280-25-022753.txt : 20250506
<SEC-HEADER>0001628280-25-022753.hdr.sgml : 20250506
<ACCEPTANCE-DATETIME>20250506170200
ACCESSION NUMBER:		0001628280-25-022753
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250506
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250506
DATE AS OF CHANGE:		20250506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		25918162

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cpix-20250506.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:993d9edc-82cf-47da-818c-67961236e0e9,g:865064d2-5480-47f2-a256-1473ed7ae5fa,d:5aad28fbdf5d4cfbac17c546d743e7bf-->
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20250506</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-24">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-25">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20250506.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-06</xbrli:startDate><xbrli:endDate>2025-05-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5aad28fbdf5d4cfbac17c546d743e7bf_1"></div><div style="min-height:29.25pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:174%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May&#160;6, 2025</ix:nonNumeric> (<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">May&#160;6, 2025</ix:nonNumeric>)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-4">CUMBERLAND PHARMACEUTICALS INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-5">Tennessee</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-33637</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-7">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-8">1600 West End Avenue, Suite 1300</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">37203</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(Address of Principal Executive Offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">615</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">255-0068</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Registrant's telephone number, including area code</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">CPIX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="text-align:right"><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5aad28fbdf5d4cfbac17c546d743e7bf_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 &#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-22">May&#160;6, 2025</ix:nonNumeric>, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three months ended March 31, 2025.  A copy of the press release is attached as </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2025q1-ex991er.htm">Exhibit 99.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.</span></div><div style="margin-top:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This information is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of 1933, as amended, or the Exchange Act. By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by Item 2.02.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Item 9.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Financial Statements and Exhibits</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;(d)  Exhibits</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.461%"><tr><td style="width:1.0%"/><td style="width:18.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.093%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:66.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2025q1-ex991er.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2025q1-ex991er.htm">Press release</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2025q1-ex991er.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2025q1-ex991er.htm">dated May 6, 2025</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5aad28fbdf5d4cfbac17c546d743e7bf_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:16.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-23">May&#160;6, 2025</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a2025q1-ex991er.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie1f5259f1c3b464f90aabb2c80390445_486"></div><div style="min-height:51.12pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:92px;margin-bottom:5pt;vertical-align:text-bottom;width:407px"></div><div style="margin-bottom:18pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NASHVILLE, Tenn. (Tuesday, May&#160;06, 2025) &#8211; Cumberland Pharmaceuticals Inc. (Nasdaq&#58; CPIX)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$11.7 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> during the first quarter of 2025, a 38% increase over the prior year period. As a result the Company generated a net profit of $1.3 million for the quarter, adjusted earnings of </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$2.4 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and cash flow from operations of $3.9 million.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland ended the quarter with approximately </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$70 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in total assets, </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$41.6 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in liabilities and </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$28.7 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of shareholders&#8217; equity.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;We are entering an exciting time for our company, as we continue to build momentum and capitalize on a range of promising opportunities,&#8221; said Cumberland Pharmaceuticals CEO A.J. Kazimi. &#8220;Our optimism is driven by strong performance from our approved brands, the expansion of international partnerships, meaningful progress across our clinical development programs and the potential for strategic acquisitions.&#34; </font></div><div id="ie1f5259f1c3b464f90aabb2c80390445_519"></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECENT COMPANY DEVELOPMENTS INCLUDE&#58;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Top-Line DMD Study Results</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In February 2025, Cumberland announced positive top-line results from the Phase II study evaluating its ifetroban product candidate in patients with Duchenne muscular dystrophy (DMD). This marks a breakthrough for these patients, as it&#8217;s the first successful Phase II study specifically targeting the cardiac complications of their condition.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">These study results were selected for a late-breaking presentation in March at the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Muscular Dystrophy Association</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Clinical &#38; Scientific Conference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  That platform allowed Cumberland to share the promising results with the global DMD community, including leading researchers, clinicians and patient advocates who are working tirelessly to improve outcomes for those affected by this devastating disease. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Next steps for Cumberland&#8217;s DMD program include further data analysis and completion of a full study report in preparation for an end-of-Phase-II meeting with the FDA to determine the requirements for the product&#8217;s approval.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Approval in China </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland's potent antibiotic, Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, received approval from the regulatory authorities in China. This provides Cumberland access to the world&#8217;s second-largest pharmaceutical market. The company expects the product to launch by the end of the year. </font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie1f5259f1c3b464f90aabb2c80390445_541"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">FINANCIAL RESULTS&#58;</font></div><div style="margin-top:8pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Revenue&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For first quarter of 2025, net revenues were </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$11.7 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and included $3.5 million for Kristalose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, $2.3 million for Sancuso</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, $1.4 million for Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and $1.3 million for Caldolor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:6pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Operating Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Total operating expenses for the quarter were </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$10.4 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Income&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The net income for the first quarter of 2025 was approximately </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$1.3 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:6pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adjusted Earnings&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Adjusted earnings for the quarter were </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$2.4 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, or </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$0.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> per share. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:4.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Balance Sheet&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> At March 31, 2025, Cumberland had approximately </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$70 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in total assets, including </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$15.1 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in cash and cash equivalents. Liabilities totaled </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$41.6 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, including $5.2 million on the company&#8217;s credit facility. Total shareholders&#8217; equity was </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$28.7 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> on March 31, 2025.<br><br></font></div><div id="ie1f5259f1c3b464f90aabb2c80390445_563"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:4.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EARNINGS REPORT CALL&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A conference call will be held today, May&#160;06, 2025, at 4&#58;30 p.m. Eastern Time to provide a company update and discuss the financial results. The link to register is</font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;register-conf.media-server.com&#47;register&#47;BIea2bc7f82dd24caea135dbe5460d9b6f</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Registered participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a &#8220;Call Me&#8221; option to have the system automatically call them at the start of the conference. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A replay of the call will be available for one year and can be accessed via Cumberland&#8217;s website or by visiting&#58; </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;edge.media-server.com&#47;mmc&#47;p&#47;wost2na9&#47;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie1f5259f1c3b464f90aabb2c80390445_585"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ABOUT CUMBERLAND PHARMACEUTICALS&#58;</font></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cumberland Pharmaceuticals Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company&#8217;s portfolio of FDA-approved brands includes&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Acetadote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) injection, for the treatment of acetaminophen poisoning&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Caldolor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) injection, for the treatment of pain and fever&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Kristalose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">lactulose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) oral, a prescription laxative, for the treatment of constipation&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Sancuso</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">granisetron) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Vaprisol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">telavancin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.</font></div><div style="margin-top:8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis and Pulmonary Fibrosis. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For more information on Cumberland&#8217;s approved products, including full prescribing information, please visit the links to the individual product websites, which can be found on the company&#8217;s website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.cumberlandpharma.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Acetadote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (acetylcysteine) Injection</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. For full prescribing and safety information, visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.acetadote.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Caldolor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (ibuprofen) Injection</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs) as well as patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.caldolor.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:8pt;text-align:justify"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Kristalose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (lactulose) Oral Solution</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing and safety information, visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.kristalose.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Sancuso</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">granisetron) Transdermal System</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sancuso is the only skin patch approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and&#47;or highly emetogenic chemotherapy. When applied 24 to 48 hours before receiving chemotherapy, the Sancuso patch slowly and continuously releases the medicine contained in the adhesive through clean and intact skin areas into the patient&#8217;s bloodstream. It can prevent CINV for chemotherapy regimens of up to five consecutive days. For full prescribing and safety information, visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.sancuso.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Vaprisol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (conivaptan hydrochloride) Injection</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vaprisol is an intravenous treatment for hyponatremia used in the critical care setting. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal. This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes free water secretion. Vaprisol is contraindicated in patients with hypovolemic hyponatremia. The coadministration of Vaprisol with potent CYP3A inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir and indinavir, is contraindicated. For full prescribing and safety information, including boxed warning, visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.vaprisol.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (telavancin) for Injection</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. Intravenous unfractionated heparin sodium is contraindicated with Vibativ administration due to artificially prolonged activated partial thromboplastin time (aPTT) test results for up to 18 hours after Vibativ administration. Vibativ is contraindicated in patients with a known hypersensitivity to telavancin. For more information, please visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.vibativ.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ABOUT CUMBERLAND EMERGING TECHNOLOGIES&#58;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland Emerging Technologies, Inc. (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.cet-fund.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN and WinHealth. The mission of CET is to advance biomedical technologies and products conceived at Vanderbilt University and other regional research centers towards the marketplace. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CET helps manage the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET&#8217;s Life Sciences Center provides laboratory space, equipment and infrastructure for CET&#8217;s activities and other early-stage life sciences ventures.</font></div><div style="margin-top:8pt"><font><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">FORWARD LOOKING STATEMENTS&#58;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland&#8217;s current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the Company&#8217;s intent, belief or expectations, and can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;seek,&#8221; &#8220;anticipate,&#8221; &#8220;look forward&#8221; and other comparable terms or the negative thereof. As with any business, all phases of Cumberland&#8217;s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland&#8217;s operation results. These factors include macroeconomic conditions, including rising interest rates and inflation, competition, an inability of manufacturers to produce Cumberland&#8217;s products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the Company&#8217;s control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), as well as the Company&#8217;s other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SOURCE&#58; Cumberland Pharmaceuticals Inc.</font></div><div style="margin-top:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><font><br></font></div><div style="padding-left:85.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.713%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investor Contact&#58;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Media Contact&#58;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shayla Simpson</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molly Aggas</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dalton Agency</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(615) 255-0068</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(704) 641-6641</font></td></tr></table></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- MORE -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br><br><br><br><br><br></font></div><div style="height:51.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie1f5259f1c3b464f90aabb2c80390445_19"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,108,413&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,964,184&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,487,925&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,701,466&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,098,859&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999,995&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,181,954&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,786,513&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,877,151&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,452,158&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventories</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,939,236&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,005,499&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,740&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,365&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,986,962&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,973,449&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,177,490&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,176,923&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742,299&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784,016&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,935,878&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,583,410&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,927,623&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,914,266&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,094&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,508&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of revolving line of credit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,220,902&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,250,955&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,519,619&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,621,729&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit - long term</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,240,733&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,176,170&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,829,054&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939,739&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,005,853&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,299,795&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,595,259&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,037,433&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;no par value&#59; 100,000,000 shares authorized&#59; 14,961,137 and 13,952,624 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,367,883&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,821,425&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,710,863)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,967,931)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,657,020&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,853,494&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316,401)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307,517)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,340,619&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,545,977&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,935,878&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,583,410&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie1f5259f1c3b464f90aabb2c80390445_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-top:5pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.001%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,713,055&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,497,701&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425,714&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,575,542&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,231,980&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154,588&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295,076&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158,253&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,463,008&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367,907&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005,330&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110,661&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,421,108&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,366,951&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291,947&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,869,250)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,709&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,746&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163,802)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,526)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253,854&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,891,030)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,670)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,442)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248,184&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,902,472)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) at subsidiary attributable to noncontrolling interests</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,884&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,791)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257,068&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,946,263)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- basic</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,942,522&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,098,022&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- diluted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,259,824&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,098,022&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie1f5259f1c3b464f90aabb2c80390445_25"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-top:5pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248,184&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,902,472)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031,584&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,685&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,184&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,184&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,212&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,754&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in non-cash contingent consideration</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,976&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230,430)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,182&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,217)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash interest expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,810&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities affecting operating activities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213,541&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,066,410)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,399&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,469&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and other assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,371&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,619&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219,493)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,825)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(600,043)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(645,542)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293,942)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,728&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,898,517&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,136,647)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property and equipment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,630)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,621)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in manufacturing facility</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,162,357)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to intangible assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,199)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,565)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,228,186)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,186)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from ATM offering, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266,334&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on line of credit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,000,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on line of credit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,035,437)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,700,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash settlement of contingent consideration</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(511,131)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630,701)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments made in connection with repurchase of common shares</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245,868)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(247,605)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,526,102)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,421,694&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,855,771)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,861&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,964,184&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,321,624&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,108,413&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,548,485&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie1f5259f1c3b464f90aabb2c80390445_28"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reconciliation of Net Income (loss) Attributable to Common Shareholders to Adjusted Earnings (loss) and Adjusted Diluted Earnings (loss) Per Share</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Unaudited)</font></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:41.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.678%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings impact</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share impact</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings impact</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share impact</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to common shareholders</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257,068&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,946,263)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; Net (income) loss at subsidiary attributable to noncontrolling interests</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,884&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,791)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248,184&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,902,472)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to net income (loss)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,670&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,442&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031,584&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.07&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,685&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,212&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,754&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125,709)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,746)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,802&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,526&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted earnings (loss) and adjusted diluted earnings (loss) per share</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,397,743&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(639,811)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,259,824&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,098,022&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="ie1f5259f1c3b464f90aabb2c80390445_307"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company provided the above adjusted supplemental financial performance measures, which are considered &#34;non-GAAP&#34; financial measures under applicable SEC rules and regulations. These financial measures should be considered supplemental to, and not as a substitute for, financial information prepared in accordance with Generally Accepted Accounting Principles (&#34;GAAP&#34;). The definition of these supplemental measures may differ from similarly titled measures used by others.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Because these supplemental financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the supplemental financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland's management believes these supplemental financial performance measures are important as they are used by management, along with financial measures in accordance with GAAP, to evaluate the Company's operating performance.  In addition, Cumberland believes that they will be used by certain investors to measure the Company's operating results. Management believes that presenting these supplemental measures provides useful information about the Company's underlying performance across reporting periods on a consistent basis by excluding items that Cumberland does not believe are indicative of its core business performance or reflect long-term strategic activities.  Certain of these items are not settled through cash payments and include&#58; depreciation, amortization, share-based compensation expense and income taxes.  Cumberland utilizes its net operating loss carryforwards to pay minimal income taxes.  In addition, the use of these financial measures provides greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including the evaluation of the Company's operating performance.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company defines these supplemental financial measures as follows&#58;</font></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12.53pt">Adjusted Earnings (loss)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">net income (loss) adjusted for the impact of income taxes, depreciation and amortization expense, share-based compensation, interest income and interest expense.  </font></div><div style="margin-top:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a) &#160;&#160;&#160;&#160;Represents the share-based compensation of Cumberland.</font></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Adjusted Diluted Earnings (loss) Per Share&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Adjusted Earnings (loss) divided by diluted weighted-average common shares outstanding. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cpix-20250506.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:993d9edc-82cf-47da-818c-67961236e0e9,g:865064d2-5480-47f2-a256-1473ed7ae5fa-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://cumberlandpharma.com/20250506" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cumberlandpharma.com/20250506">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20250506_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20250506_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cpix-20250506_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:993d9edc-82cf-47da-818c-67961236e0e9,g:865064d2-5480-47f2-a256-1473ed7ae5fa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6a7f0952-785a-4d78-8e01-96a9470f5317_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a7cef98f-d13a-46e7-b603-baa60977a721_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_bd6dec44-42ba-463c-b610-2bc578afb168_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7e1d0254-bb9b-4864-ab38-5dbc2c30fefe_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_14fca4e0-66c3-49a8-900e-baa5a56269ed_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_a7a5d42d-637b-4333-8209-2034ddbb8b77_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5ae8377c-e74f-4586-8d42-fa322458425f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6473e203-2179-4b19-b324-4601a7d6915a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6c732ab8-cddb-42af-bff4-ddd97b05eeb3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_3979fb2d-6ea6-4685-8a63-135452c5acf4_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_d6f109ad-493e-4a71-9bc2-7bdc3d56f621_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_116402b5-d83a-4e10-ad1c-cd8ea63003ef_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_54191a88-e966-4fbc-b068-a4dd10f1f0f3_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_72f3996f-4526-4a0d-9747-bcce259831be_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6ed8400e-04ea-4582-806e-eda703bb6877_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8367a6fd-d9d9-41d4-99e9-b4351f061df8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_61284c54-eb47-42fd-a6b5-e8e5aff55014_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cd48241a-4a02-4393-9e79-704b2f38bbc0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7ca3afbf-dbbb-44d6-a3a3-32f947e3f535_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e38cf467-eb15-4afc-b575-c73d294b2a3b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_0f04d0de-6598-4aa7-8f24-53f21df7dd7b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a3426333-9da8-4512-81be-22a9b1216a22_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_25b8d803-a8b0-4472-8b8b-7027f1ec3a8d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cpix-20250506_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:993d9edc-82cf-47da-818c-67961236e0e9,g:865064d2-5480-47f2-a256-1473ed7ae5fa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="cpix-20250506.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8ed8e19b-b64a-4edb-91cb-637872d51572" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_DocumentType_8ed8e19b-b64a-4edb-91cb-637872d51572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_013c9715-44cd-4f59-99fd-904073a07a1e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_DocumentPeriodEndDate_013c9715-44cd-4f59-99fd-904073a07a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ab96d685-6487-41b9-ac4c-e2d1016face5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_EntityRegistrantName_ab96d685-6487-41b9-ac4c-e2d1016face5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bf418517-6e0f-4b88-96f1-a4c90b13000f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_EntityCentralIndexKey_bf418517-6e0f-4b88-96f1-a4c90b13000f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8b13748f-f1dc-4695-9692-ffc1576aadee" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_AmendmentFlag_8b13748f-f1dc-4695-9692-ffc1576aadee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d95d9349-cc4e-496d-9b7c-6bcb1934ef9f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d95d9349-cc4e-496d-9b7c-6bcb1934ef9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_055fd790-58b3-4655-9eda-6b973598d4f2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_EntityFileNumber_055fd790-58b3-4655-9eda-6b973598d4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1947fac6-8d06-400c-b8c7-c881b1132ce0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_EntityTaxIdentificationNumber_1947fac6-8d06-400c-b8c7-c881b1132ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f6967eb0-7efa-4677-8c8f-e246115f622c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_CityAreaCode_f6967eb0-7efa-4677-8c8f-e246115f622c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_09f6bb46-3b51-441a-a42c-433af428cbcd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_LocalPhoneNumber_09f6bb46-3b51-441a-a42c-433af428cbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_941947c2-a813-4516-9917-f3da9b954235" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_WrittenCommunications_941947c2-a813-4516-9917-f3da9b954235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_892a738d-9e82-42aa-9fb8-c8c1ed90e6e9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_SolicitingMaterial_892a738d-9e82-42aa-9fb8-c8c1ed90e6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_636ca561-bcca-4a83-b1b5-46b22a3af5ee" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_PreCommencementTenderOffer_636ca561-bcca-4a83-b1b5-46b22a3af5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_27605bac-0126-4aac-8eec-cd16cf3e8f8a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_27605bac-0126-4aac-8eec-cd16cf3e8f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_923b2fa2-aa7a-446a-b062-5ab35f2cf592" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_Security12bTitle_923b2fa2-aa7a-446a-b062-5ab35f2cf592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_10aab5b5-f687-41ab-950f-a61881811f1b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_TradingSymbol_10aab5b5-f687-41ab-950f-a61881811f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d40548af-1ad8-4748-983d-af1ed065ce4b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_SecurityExchangeName_d40548af-1ad8-4748-983d-af1ed065ce4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_51c8a583-4dab-4fd7-bb83-65ab6f7c3cf2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_EntityEmergingGrowthCompany_51c8a583-4dab-4fd7-bb83-65ab6f7c3cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_bd6e1e0d-47b3-4949-a72d-bcd0ec275dc5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_EntityAddressAddressLine1_bd6e1e0d-47b3-4949-a72d-bcd0ec275dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_df19ff3d-9db4-4437-a90d-758823d38686" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_EntityAddressPostalZipCode_df19ff3d-9db4-4437-a90d-758823d38686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_62cef617-b15e-4e9e-afab-d7b0fa30f03b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_EntityAddressCityOrTown_62cef617-b15e-4e9e-afab-d7b0fa30f03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d0260348-da37-47b1-b22c-c34554719752" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bca11cb9-558f-4ac4-978c-592ac5d2733e" xlink:to="loc_dei_EntityAddressStateOrProvince_d0260348-da37-47b1-b22c-c34554719752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !< 9<# 2(  A$! Q$!_\0
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MVM%MMH_KMHHHKX@]L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3VOFI,O]47[!G[1FI_M;_L>?L]?M'ZWHMIX=UWXM?#C1_$VOZ+ISSOIFG^(
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M)(9)$+*&R.'^%_QF\)?$ZQCCLKVWL/$T%NDFK>&;F=8]0M2% >YM(YO+EO\
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M/'_P=:_\$\XXXT;X9?M3DI&BDCP'\.B-RJ >OQ:!QD<'N*^!_P#@I=_P<=_
M_P#:7_90\6?"?]D"[_:S^"OQRUCQ+X)O_#WCZP.G?#6[L--TCQ'97VOV,/BO
MX??$^]\3VAU32XI[(VMG \-\)#;W8$+DTL!X=\9UL?A82RG'Y?"IB8)YA4A*
MG3PD'47^U5)TYJ<84HWFY0O)6NEU*Q?&O#%+"8B<<QP>-E"C.2P=.?-/$-0O
M[&,)1LW4T@DURW=G8_M$\"^!O!/PT\)Z)X$^'/A7P[X'\$^&K0:=X=\)^$M(
ML-!\.:%8B1YA9:3H^F06VGV%J)I99!!:P11"21V"[F)/\>O[ G_*T'^W7_V
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M<JK<28;,<RPV$K3XFS.K"G6FX2E3E[&$9I6VE*$TO.+Z(_IUKRKXY?&/P/\
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M0^ _"VM:M=K;0QVUNMSJ.I:5<WDZP6\45O")9G$<,4<2!8T51B_\,W_L\?\
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M*ES/]Y4:@M3]3O#WAOP]X2TBUT#PKH6C>&M"L?.^Q:+X?TNQT;2;,7%Q+=7
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MOW9--.FT[WM?4\P^$FN_%CQ%X3.H_&;X>^%/AEXQ_M2]@'AKP=\1+SXGZ/\
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? "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>May 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  06,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CUMBERLAND PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1600 West End Avenue, Suite 1300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #V(IEI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( #V(IEH$= %G[@   "L"   1
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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M9A2<V#P ]Y=2ZN.)V=Z6_YT8_@M02P,$%     @ /8BF6I^@&_"Q @  X@P
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ /8BF6D;'34B5    S0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  ]B*9:!'0!9^X    K @  $0              @ '#    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  ]B*9:F5R<(Q &  "<)P  $P
M    @ '@ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( #V(IEI=
MO5<F900  *D0   8              " @2$(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  ]B*9:GZ ;\+$"  #B#   #0
M    @ &\#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( #V(IEJ7BKL<P
M !,"   +              "  9@/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M #V(IEH<.&7J/P$  #P"   /              "  8$0  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    "  ]B*9:)!Z;HJT   #X 0  &@
M@ 'M$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  ]
MB*9:99!YDAD!  #/ P  $P              @ '2$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"   <%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cpix-20250506.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="cpix-20250506.htm">cpix-20250506.htm</File>
    <File>cpix-20250506.xsd</File>
    <File>cpix-20250506_lab.xml</File>
    <File>cpix-20250506_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cpix-20250506.htm": {
   "nsprefix": "cpix",
   "nsuri": "http://cumberlandpharma.com/20250506",
   "dts": {
    "inline": {
     "local": [
      "cpix-20250506.htm"
     ]
    },
    "schema": {
     "local": [
      "cpix-20250506.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20250506_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20250506_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 25
   },
   "report": {
    "R1": {
     "role": "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "shortName": "Document and Entity Information Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20250506.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20250506.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-25-022753-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-022753-xbrl.zip
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MD#*E]=!Q$CT.6J,+RC!WH3QX@_!A;J*!',&=,&FEAE8?4F\ #B@GPU1Z:0
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M7]7U":Z#SC/E9\-(89X+Z%,>5U_5I IRZ,U%.?C0#!FIV(=B?K1\</9,*Y0
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MC0+ADUQLLZO(P>6+&6?.K-%W@E?5W[IAS;,:6UY:G5'$W?F$,9[R4A3)+D.
MP[BN?!ZI%*1Y#R0CY[:4TJ<8'0<A/^%>M8>I>,2"MZ2I%;UN!FP<,'(CAB,Y
ML_172=S:%/P4(=+K]/M,5J+V&*'6!0*5[*U-T@_@[P#6[*AJ"%M(7X8W'B36
M$4GGB6LZI\1RG)IAN*WUA?%Y)#PF83UI&O8I<6VSYL(_R]+ZLX+"NXG!/_N1
M!QV#PM0<JY%/GZ\O2&WO9W2M^J_P:R/K'\!EMG=P_I9MU9O.KG;CFNO(YRL
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MK=&R7Z:SSEK-5J>,/W'*>'4B>'4B^$N>"'[P&T"4U>RAU22].!J2:%((E7F
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M)/ CZT9W?!J6E>EH%'#<ZL\"TA,A"ST!GT8\[D4Q],+C9,B93,'84'(_$-Z
M8#EQ+PHE-!E#"S_]T+#?AE%8^ZW3^:*^S+23/TM -'A,&+P,V(@"<'-Q3N(T
M@$L8)HYY/PU4]K:L$^B[Y*L:D8,H#7S2G7O_W B2B*KVPB@A#)I6-0\3D8 M
M)3 @.M.J"-4(5<;X*.8CAHV)D##/ Z%5([\7R8#\QD.PO$$P)AW *R,D&GP
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M(N\73[#$"O?U^-W]B?:C?>?^^-U_ 5!+ 0(4 Q0    ( #V(IEJGXQFJ2#8
M #G- @ 3              "  0    !A,C R-7$Q+65X.3DQ97(N:'1M4$L!
M A0#%     @ /8BF6FJ&=4^=#P  RG   !$              ( !>38  &-P
M:7@M,C R-3 U,#8N:'1M4$L! A0#%     @ /8BF6NE;^!I] @  9@<  !$
M             ( !148  &-P:7@M,C R-3 U,#8N>'-D4$L! A0#%     @
M/8BF6GML>OXK"@  ?54  !4              ( !\4@  &-P:7@M,C R-3 U
M,#9?;&%B+GAM;%!+ 0(4 Q0    ( #V(IEH&!N%_P08  $,Q   5
M      "  4]3  !C<&EX+3(P,C4P-3 V7W!R92YX;6Q02P4&      4 !0!%
) 0  0UH

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>cpix-20250506_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cpix-20250506.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2025-05-06</startDate>
            <endDate>2025-05-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-24">0001087294</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-25">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-05-06</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-05-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-4">CUMBERLAND PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-5">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-33637</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-7">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-8">1600 West End Avenue, Suite 1300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">255-0068</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-22">2025-05-06</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-23">2025-05-06</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
